[1] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent, and A. Jemal, “Global cancer statistics, 2012,” CA Cancer J Clin, vol. 65, no. 2, pp. 87-108, Mar, 2015.
[2] R. G. Simonetti, C. Camma, F. Fiorello, M. Cottone, M. Rapicetta, L. Marino, G. Fiorentino, A. Craxi, A. Ciccaglione, R. Giuseppetti, T. Stroffolini, and L. Pagliaro, “Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study,” Ann Intern Med, vol. 116, no. 2, pp. 97-102, Jan 15, 1992.
[3] H. B. El-Serag, “Epidemiology of viral hepatitis and hepatocellular carcinoma,” Gastroenterology, vol. 142, no. 6, pp. 1264-1273.e1, May, 2012.
[4] Y. Shiratori, F. Imazeki, M. Moriyama, M. Yano, Y. Arakawa, O. Yokosuka, T. Kuroki, S. Nishiguchi, M. Sata, G. Yamada, S. Fujiyama, H. Yoshida, and M. Omata, “Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy,” Ann Intern Med, vol. 132, no. 7, pp. 517-24, Apr 4, 2000.
[5] H. Yoshida, Y. Shiratori, M. Moriyama, Y. Arakawa, T. Ide, M. Sata, O. Inoue, M. Yano, M. Tanaka, S. Fujiyama, S. Nishiguchi, T. Kuroki, F. Imazeki, O. Yokosuka, S. Kinoyama, G. Yamada, and M. Omata, “Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy,” Ann Intern Med, vol. 131, no. 3, pp. 174-81, Aug 3, 1999.
[6] V. Mazzaferro, R. Romito, M. Schiavo, L. Mariani, T. Camerini, S. Bhoori, L. Capussotti, F. Calise, R. Pellicci, G. Belli, A. Tagger, M. Colombo, F. Bonino, P. Majno, and J. M. Llovet, “Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis,” Hepatology, vol. 44, no. 6, pp. 1543-54, Dec, 2006.
[7] Y. C. Shen, C. Hsu, L. T. Chen, C. C. Cheng, F. C. Hu, and A. L. Cheng, “Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach,” J Hepatol, vol. 52, no. 6, pp. 889-94, Jun, 2010.
[8] Y. Shiratori, S. Shiina, T. Teratani, M. Imamura, S. Obi, S. Sato, Y. Koike, H. Yoshida, and M. Omata, “Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus,” Ann Intern Med, vol. 138, no. 4, pp. 299-306, Feb 18, 2003.
[9] T. Minami, R. Tateishi, S. Shiina, R. Nakagomi, M. Kondo, N. Fujiwara, S. Mikami, M. Sato, K. Uchino, K. Enooku, H. Nakagawa, Y. Asaoka, Y. Kondo, H. Yoshida, and K. Koike, “Comparison of improved prognosis between hepatitis B- and hepatitis C-related hepatocellular carcinoma,” Hepatol Res, vol. 45, no. 10, pp. E99-e107, Oct, 2015.
[10] K. Chayama, F. Suzuki, Y. Karino, Y. Kawakami, K. Sato, T. Atarashi, A. Naganuma, T. Watanabe, Y. Eguchi, H. Yoshiji, M. Seike, Y. Takei, K. Kato, K. Alves, M. Burroughs, R. Redman, D. L. Pugatch, T. J. Pilot-Matias, P. Krishnan, R. K. Oberoi, W. Xie, and H. Kumada, “Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis,” J Gastroenterol, vol. 53, no. 4, pp. 557-565, Apr, 2018.
[11] H. Kumada, Y. Suzuki, Y. Karino, K. Chayama, N. Kawada, T. Okanoue, Y. Itoh, S. Mochida, H. Toyoda, H. Yoshiji, S. Takaki, N. Yatsuzuka, E. Yodoya, T. Iwasa, G. Fujimoto, M. N. Robertson, S. Black, L. Caro, and J. Wahl, “The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study,” J Gastroenterol, vol. 52, no. 4, pp. 520-533, Apr, 2017.
[12] M. Mizokami, O. Yokosuka, T. Takehara, N. Sakamoto, M. Korenaga, H. Mochizuki, K. Nakane, H. Enomoto, F. Ikeda, M. Yanase, H. Toyoda, T. Genda, T. Umemura, H. Yatsuhashi, T. Ide, N. Toda, K. Nirei, Y. Ueno, Y. Nishigaki, J. Betular, B. Gao, A. Ishizaki, M. Omote, H. Mo, K. Garrison, P. S. Pang, S. J. Knox, W. T. Symonds, J. G. McHutchison, N. Izumi, and M. Omata, “Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial,” Lancet Infect Dis, vol. 15, no. 6, pp. 645-53, Jun, 2015.
[13] “Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts,” J Hepatol, vol. 65, no. 4, pp. 734-740, Oct, 2016.
[14] G. Cabibbo, S. Petta, V. Calvaruso, I. Cacciola, M. R. Cannavo, S. Madonia, M. Distefano, L. Larocca, T. Prestileo, F. Tine, G. Bertino, L. Giannitrapani, F. Benanti, A. Licata, I. Scalisi, G. Mazzola, F. Cartabellotta, N. Alessi, M. Barbara, M. Russello, G. Scifo, G. Squadrito, G. Raimondo, A. Craxi, V. Di Marco, and C. Camma, “Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study,” Aliment Pharmacol Ther, vol. 46, no. 7, pp. 688- 695, Oct, 2017.
[15] F. Conti, F. Buonfiglioli, A. Scuteri, C. Crespi, L. Bolondi, P. Caraceni, F. G. Foschi, M. Lenzi, G. Mazzella, G. Verucchi, P. Andreone, and S. Brillanti, “Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals,” J Hepatol, vol. 65, no. 4, pp. 727- 33, Oct, 2016.
[16] M. Reig, Z. Marino, C. Perello, M. Inarrairaegui, A. Ribeiro, S. Lens, A. Diaz, R. Vilana, A. Darnell, M. Varela, B. Sangro, J. L. Calleja, X. Forns, and J. Bruix, “Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy,” J Hepatol, vol. 65, no. 4, pp. 719-26, Oct, 2016.
[17] T. Minami, R. Tateishi, R. Nakagomi, N. Fujiwara, M. Sato, K. Enooku, H. Nakagawa, Y. Asaoka, Y. Kondo, S. Shiina, and K. Koike, “The impact of directacting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma,” J Hepatol, vol. 65, no. 6, pp. 1272-1273, Dec, 2016.
[18] R. Lencioni, and J. M. Llovet, “Modified RECIST (mRECIST) assessment for hepatocellular carcinoma,” Semin Liver Dis, vol. 30, no. 1, pp. 52-60, Feb, 2010.
[19] G. Torzilli, M. Minagawa, T. Takayama, K. Inoue, A. M. Hui, K. Kubota, K. Ohtomo, and M. Makuuchi, “Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy,” Hepatology, vol. 30, no. 4, pp. 889-93, Oct, 1999.
[20] J. Bruix, and M. Sherman, “Management of hepatocellular carcinoma: an update,” Hepatology, vol. 53, no. 3, pp. 1020-2, Mar, 2011.
[21] M. Nishibatake Kinoshita, T. Minami, R. Tateishi, T. Wake, R. Nakagomi, N. Fujiwara, M. Sato, K. Uchino, K. Enooku, H. Nakagawa, Y. Asaoka, S. Shiina, and K. Koike, “Impact of direct-acting antivirals on early recurrence of HCVrelated HCC: Comparison with interferon-based therapy,” J Hepatol, vol. 70, no. 1, pp. 78-86, Jan, 2019.
[22] H. A. Torres, J. N. Vauthey, M. P. Economides, P. Mahale, and A. Kaseb, “Hepatocellular carcinoma recurrence after treatment with direct-acting antivirals: First, do no harm by withdrawing treatment,” J Hepatol, vol. 65, no. 4, pp. 862-864, Oct, 2016.
[23] Q. L. Zeng, Z. Q. Li, H. X. Liang, G. H. Xu, C. X. Li, D. W. Zhang, W. Li, C. Y. Sun, F. S. Wang, and Z. J. Yu, “Unexpected high incidence of hepatocellular carcinoma in patients with hepatitis C in the era of DAAs: Too alarming?,” J Hepatol, vol. 65, no. 5, pp. 1068-1069, Nov, 2016.
[24] K. Ikeda, Y. Kawamura, M. Kobayashi, Y. Kominami, S. Fujiyama, H. Sezaki, T. Hosaka, N. Akuta, S. Saitoh, F. Suzuki, Y. Suzuki, Y. Arase, and H. Kumada, “Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma,” Dig Dis Sci, vol. 62, no. 10, pp. 2932-2942, Oct, 2017.
[25] P. Kolly, O. Waidmann, J. Vermehren, C. Moreno, I. Vogeli, T. Berg, D. Semela, S. Zeuzem, and J. F. Dufour, “Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study,” J Hepatol, vol. 67, no. 4, pp. 876-878, Oct, 2017.
[26] H. Nagata, M. Nakagawa, Y. Asahina, A. Sato, Y. Asano, T. Tsunoda, M. Miyoshi, S. Kaneko, S. Otani, F. Kawai-Kitahata, M. Murakawa, S. Nitta, Y. Itsui, S. Azuma, S. Kakinuma, T. Nouchi, H. Sakai, M. Tomita, and M. Watanabe, “Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C,” J Hepatol, vol. 67, no. 5, pp. 933-939, Nov, 2017.
[27] S. Petta, G. Cabibbo, M. Barbara, S. Attardo, L. Bucci, F. Farinati, E. G. Giannini, F. Tovoli, F. Ciccarese, G. L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, R. Virdone, F. Marra, M. Felder, F. Morisco, L. Benvegnu, A. Gasbarrini, G. Svegliati-Baroni, F. G. Foschi, A. Olivani, A. Masotto, G. Nardone, A. Colecchia, M. Persico, V. Boccaccio, A. Craxi, S. Bruno, F. Trevisani, and C. Camma, “Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon,” Aliment Pharmacol Ther, vol. 45, no. 1, pp. 160-168, Jan, 2017.
[28] V. Virlogeux, P. Pradat, K. Hartig-Lavie, F. Bailly, M. Maynard, G. Ouziel, D. Poinsot, F. Lebosse, M. Ecochard, S. Radenne, S. Benmakhlouf, J. Koffi, P. Lack, C. Scholtes, A. C. Uhres, C. Ducerf, J. Y. Mabrut, A. Rode, M. Levrero, C. Combet, P. Merle, and F. Zoulim, “Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C,” Liver Int, vol. 37, no. 8, pp. 1122-1127, Aug, 2017.
[29] C. Zavaglia, S. Okolicsanyi, L. Cesarini, C. Mazzarelli, V. Pontecorvi, A. Ciaccio, M. Strazzabosco, and L. S. Belli, “Is the risk of neoplastic recurrence increased after prescribing direct-acting antivirals for HCV patients whose HCC was previously cured?,” J Hepatol, vol. 66, no. 1, pp. 236-237, Jan, 2017.
[30] R. Tateishi, S. Shiina, H. Yoshida, T. Teratani, S. Obi, N. Yamashiki, H. Yoshida, M. Akamatsu, T. Kawabe, and M. Omata, “Prediction of recurrence of hepatocellular carcinoma after curative ablation using three tumor markers,” Hepatology, vol. 44, no. 6, pp. 1518-27, Dec, 2006.
[31] Y. Sato, K. Nakata, Y. Kato, M. Shima, N. Ishii, T. Koji, K. Taketa, Y. Endo, and S. Nagataki, “Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein,” N Engl J Med, vol. 328, no. 25, pp. 1802-6, Jun 24, 1993.
[32] K. Taketa, Y. Endo, C. Sekiya, K. Tanikawa, T. Koji, H. Taga, S. Satomura, S. Matsuura, T. Kawai, and H. Hirai, “A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma,” Cancer Res, vol. 53, no. 22, pp. 5419-23, Nov 15, 1993.
[33] N. Yamashiki, H. Yoshida, R. Tateishi, S. Shiina, T. Teratani, H. Yoshida, Y. Kondo, T. Oki, T. Kawabe, and M. Omata, “Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment,” J Gastroenterol Hepatol, vol. 22, no. 12, pp. 2155-60, Dec, 2007.
[34] H. Imamura, Y. Matsuyama, E. Tanaka, T. Ohkubo, K. Hasegawa, S. Miyagawa, Y. Sugawara, M. Minagawa, T. Takayama, S. Kawasaki, and M. Makuuchi, “Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy,” J Hepatol, vol. 38, no. 2, pp. 200- 7, Feb, 2003.
[35] G. Cabibbo, S. Petta, M. Barbara, G. Missale, R. Virdone, E. Caturelli, F. Piscaglia, F. Morisco, A. Colecchia, F. Farinati, E. Giannini, F. Trevisani, A. Craxi, M. Colombo, and C. Camma, “A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma,” Liver Int, vol. 37, no. 8, pp. 1157-1166, Aug, 2017.
[36] G. Cabibbo, S. Petta, M. Barbara, S. Attardo, L. Bucci, F. Farinati, E. G. Giannini, G. Negrini, F. Ciccarese, G. L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, R. Virdone, F. Marra, A. Mega, F. Morisco, L. Benvegnu, A. Gasbarrini, G. Svegliati-Baroni, F. G. Foschi, A. Olivani, A. Masotto, G. Nardone, A. Colecchia, M. Persico, A. Craxi, F. Trevisani, and C. Camma, “Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma,” J Hepatol, vol. 67, no. 1, pp. 65-71, Jul, 2017.